Biotech In The Balance – Dr Jeremy M Levin

This is not a matter of corporate social responsibility slogans. It is a matter of survival—for communities and for the industry itself. Part III has argued that the promise of biotechnology depends not only on discovery, but on the physical and institutional structures that carry ideas into reality. We have explored the BIOBUILD thesis to think about resilient capacity in an age of shocks, and we have sketched how policy, corporate strategy, and capital can align with that thesis.

The next question is not only what we build, but how we lead. Infrastructure alone does not guarantee wise use. Plants, regulations, and data systems will be steered by people: boards, executives, investors, regulators, and citizens. Part IV turns to them. It asks what kind of leadership, governance, and courage are needed if this built capacity is to serve patients, protect open societies, and justify the trust placed in us. 1kitap1.com/en Part IV “The hottest places in hell are reserved for those who, in a period of moral crisis, maintain their neutrality.”

—often attributed to Dante Alighieri 1kitap1.com/en In stable times, leadership can seem like a matter of optimization. Targets are clear, the rules of the game are predictable, and the task is to execute a known strategy more efficiently than competitors. The mark of a good leader is then measured in small percentage gains. The job is hard, but it is bounded. We are not in stable times. The ground is moving under the industry: politically, economically, technologically, and socially. Institutions that once felt solid are under stress.

Rules that governed markets and science are contested. Trust, which takes years to build, can be lost in days. In such conditions, the true purpose of leadership comes into focus. Leaders are not there simply to steer through a forecast.

Dr. Levin has written a brilliant, comprehensive, compelling, and important book that makes an undeniable case for change. With clarity and specificity, he outlines the critical decisions and concrete steps that executives, government officials, board members, and investors need to make to ensure the health of the industry as well as the health of the public. —Bart Friedman, Chair, Giant Eagle Five years after the development of the Covid vaccine, the complex web of public and private institutions on which the success of the biotechnology industry depends is under attack.

Jeremy Levin offers a clear-eyed diagnosis of the industry’s ills and a comprehensive set of prescriptions to ensure that this critical industry continues to meet the challenge of advancing and protecting public health in the United States and across the globe. —Jim Millstein, Former Chief Restructuring Officer, U.S. Department of the Treasury, Co- Chairman, Guggenheim Securities LLC Biotech in the Balance by Dr. Jeremy M. Levin is a timely and thought-provoking exploration of the critical role biotechnology plays in shaping global health, economies, and societies.

Dr. Levin offers a compelling roadmap for safeguarding the integrity and future of this vital industry in an age of growing distrust. An essential read for industry leaders, policymakers, and investors. —Sol J. Barer, PhD, Former Chairman and CEO, Celgene Corporation, Chairman, Board of Directors, Teva Pharmaceutical Industries In the face of dramatic changes and continuing pressures on the life sciences industry, Jeremy Levin has created a roadmap to restore the structural foundation and leadership position of one of the shining examples of creativity in the United States.

His 10 Commitments are guiding principles that provide clarity and purpose for those who create new medicines for people in need throughout the world. —Kenneth I. Moch, President, Euclidean Life Science Advisors LLC In an industry where blockbuster success is a trap, where Wall Street demands that $50 billion companies grow by another $5 billion annually, Jeremy Levin offers a radical alternative: tell the truth.

About risk. About uncertainty. About limits, including the limits to synergies that may never materialize. Biotech in the Balance is an exceptional blueprint for life sciences leaders who want to build companies that outlast their founders and the pressure of the next earnings call, those who understand that long-term science requires long-term capital, not financial engineering.

This is a short excerpt from the opening of “” by Unknown, quoted for review and introduction purposes. All rights belong to the copyright holders.

Book Information

• Unique ID: 8f9e4b8b0d150119
• File Extension: .pdf
• File Size: 4,349,845 bytes (4.148 MB)
• Title: –
• Author: Unknown
• Pages: 131
• Language: English (en)

Reading & Word Statistics

• Estimated Reading Time: 173.25 minutes
• Total Words: 34,651
• Total Characters: 231,145
• Average Words per Page: 264.51
• Average Characters per Page: 1764.47

Most Frequent Words

biotechnology (119), https (101), public (97), science (89), health (89), people (89), patients (84), one (81), industry (79), global (73), work (73), companies (71), book (70), trust (69), drug (68), www (67), risk (66), means (66), investors (63), regulators (60), capital (59), political (59), world (58), also (58), see (57), supply (57), many (54), data (54), part (52), biotech (48), covid (47), biobuild (47), time (47), manufacturing (47), com (45), leaders (45), trial (45), clinical (45), life (43), cannot (42), org (42), institutions (41), new (41), report (41), every (40), chains (40), company (40), real (39), capacity (39), research (38), countries (38), make (37), truth (37), often (36), decisions (35), societies (35), medicines (35), even (35), trials (35), development (34), now (34), vaccine (34), united (33), states (33), leadership (33), strategic (33), made (33), independent (33), policy (32), between (32), long (32), systems (32), best (32), commitments (31), politics (31), commitment (31), want (30), rather (30), whether (30), boards (30), treat (30), years (29), long-term (29), value (29), organization (29), pressure (28), clear (28), disease (28), support (28), business (27), choices (27), promise (27), tools (27), resilience (27), drugs (26), become (26), safety (26), percent (26), regulatory (26), culture (26).

PDF Download